SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001600132-23-000049
Filing Date
2023-05-15
Accepted
2023-05-15 16:54:26
Documents
14
Period of Report
2023-05-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K blph-20230515x8k.htm   iXBRL 8-K 45346
2 EX-99.1 blph-20230515xex99d1.htm EX-99.1 117425
3 GRAPHIC blph-20230515xex99d1001.jpg GRAPHIC 6627
  Complete submission text file 0001600132-23-000049.txt   300030

Data Files

Seq Description Document Type Size
4 EX-101.SCH blph-20230515.xsd EX-101.SCH 3141
5 EX-101.LAB blph-20230515_lab.xml EX-101.LAB 15266
6 EX-101.PRE blph-20230515_pre.xml EX-101.PRE 9668
8 EXTRACTED XBRL INSTANCE DOCUMENT blph-20230515x8k_htm.xml XML 4690
Mailing Address 184 LIBERTY CORNER ROAD, SUITE 302 WARREN NJ 07059
Business Address 184 LIBERTY CORNER ROAD, SUITE 302 WARREN NJ 07059 908-574-4770
Bellerophon Therapeutics, Inc. (Filer) CIK: 0001600132 (see all company filings)

IRS No.: 473116175 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36845 | Film No.: 23923787
SIC: 2834 Pharmaceutical Preparations